근위축성측삭경화증의 SOD1-G93A 유전자 이식 마우스모델에서 라파마이신의 신경보호효과
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 안석원 | - |
dc.contributor.author | 전계선 | - |
dc.contributor.author | 박광열 | - |
dc.contributor.author | 홍윤호 | - |
dc.contributor.author | 이광우 | - |
dc.contributor.author | 성정준 | - |
dc.date.available | 2019-05-28T11:37:34Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1229-6414 | - |
dc.identifier.issn | 2288-1026 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/19258 | - |
dc.description.abstract | Background: The autophagy is the major route for lysosomal degradation of misfolded protein aggregates and oxidative cell components. We hypothesized that rapamycin (autophagy enhancer) would prolong the survival of motor neuron and suppress the disease progression in amyotrophic lateral sclerosis (ALS). Methods: A total of 24 transgenic mice harboring the human G93A mutated SOD1 gene were used. The clinical status involving rotarod test and survival, and biochemical study of ALS mice model were evaluated. Results: The onset of symptoms was significantly delayed in the rapamycin administration group compared with the control group. However, after the clinical symptom developed, the rapamycin exacerbated the disease progression and shortened the survival of ALS mice model, and apoptosis signals were up-regulated compared with control group. Conclusions: Even though further detailed studies on the relevancy between autophagy and ALS will be needed, our results revealed that the rapamycin administration was not effective for being novel promising therapeutic strategy in ALS transgenic mice and exacerbated the apoptosis. | - |
dc.format.extent | 6 | - |
dc.publisher | 대한임상신경생리학회 | - |
dc.title | 근위축성측삭경화증의 SOD1-G93A 유전자 이식 마우스모델에서 라파마이신의 신경보호효과 | - |
dc.title.alternative | Neuroprotective Effect of Rapamycin (Autophagy Enhancer) in Transgenic SOD1-G93A Mice of Amyotrophic Lateral Sclerosis | - |
dc.type | Article | - |
dc.identifier.bibliographicCitation | Annals of Clinical Neurophysiology, v.15, no.2, pp 53 - 58 | - |
dc.identifier.kciid | ART001829901 | - |
dc.description.isOpenAccess | N | - |
dc.citation.endPage | 58 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 53 | - |
dc.citation.title | Annals of Clinical Neurophysiology | - |
dc.citation.volume | 15 | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Autophagy | - |
dc.subject.keywordAuthor | Rapamycin | - |
dc.subject.keywordAuthor | Amyotrophic lateral sclerosis | - |
dc.subject.keywordAuthor | ALS | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.